DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology as well as the Chemotherapy Induced Peripheral Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chemotherapy Induced Peripheral Neuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Peripheral Neuropathy Market Forecast

Some of the key facts of the Chemotherapy Induced Peripheral Neuropathy Market Report: 

The Chemotherapy Induced Peripheral Neuropathy market size was valued approximately USD 15 Billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
The total incident population of CIPN in the 7MM countries was approximately 1,619,000 in 2022, and it is anticipated to grow at a CAGR of 1.3% from 2019 to 2032
Of the total CIPN cases in the US in 2022, which also included cases of lung, colorectal, pancreatic, and multiple myeloma cancer, breast cancer accounted for 14% (or 92,000 cases)
Germany had the biggest incident population of CIPN among the European nations in 2022, with 175,000 cases, followed by France, which had 131,500 cases. However, with 80,000 occurrences in 202, Spain had the lowest incident population of CIPN
According to statistics from 2022, platinum medicines accounted for the majority of CIPN incident instances based on chemotherapeutic agents in the US, with 321,000 cases, followed by taxanes with 203,000 cases and vincaalkaloids with 116,000 cases.
Key Chemotherapy Induced Peripheral Neuropathy Companies: Wex Pharmaceuticals, Esteve, AlgoTherapeutix, WinSanTor, Inc, Hoffmann-La Roche, Millennium Pharma, NeoTherapeutics, Lee’s Pharma, NEMA Research, Inc., and others
Key Chemotherapy Induced Peripheral Neuropathy Therapies: HALNEURON, E-52862 (MR309), ATX01, WST-057 Active, Olesoxime (TRO19622), Tetrodotoxi, Acupuncture, leteprinim potassium (Neotrofin), Acetylcarnitine, Cesamet (nabilone), and others
According to a study, different medications are widely used to treat CIPN. According to the survey, the most often prescribed medications are topical analgesics, SNRIs (serotonin/norepinephrine reuptake inhibitors), TCAs (tricyclic antidepressants), and opioid analgesics.
The Chemotherapy Induced Peripheral Neuropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy Induced Peripheral Neuropathy pipeline products will significantly revolutionize the Chemotherapy Induced Peripheral Neuropathy market dynamics.

Chemotherapy Induced Peripheral Neuropathy Overview

Anticancer medications such as platinum, taxanes, epiphilones, vinca alkaloids, and newer agents like bortezomib frequently cause CIPN complications that are dose-dependent. It not only results in dose reduction or therapy termination, but also lowers cancer survivors’ quality of life.

Get a Free sample for the Chemotherapy Induced Peripheral Neuropathy Market Report 

https://www.delveinsight.com/report-store/cipn-market

Chemotherapy Induced Peripheral Neuropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chemotherapy Induced Peripheral Neuropathy Epidemiology Segmentation:

The Chemotherapy Induced Peripheral Neuropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chemotherapy Induced Peripheral Neuropathy
Prevalent Cases of Chemotherapy Induced Peripheral Neuropathy by severity
Gender-specific Prevalence of Chemotherapy Induced Peripheral Neuropathy
Diagnosed Cases of Episodic and Chronic Chemotherapy Induced Peripheral Neuropathy

Download the report to understand which factors are driving Chemotherapy Induced Peripheral Neuropathy epidemiology trends @ Chemotherapy Induced Peripheral Neuropathy Epidemiology Forecast

Chemotherapy Induced Peripheral Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Peripheral Neuropathy market or expected to get launched during the study period. The analysis covers Chemotherapy Induced Peripheral Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chemotherapy Induced Peripheral Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chemotherapy Induced Peripheral Neuropathy Therapies and Key Companies

HALNEURON: Wex Pharmaceuticals
E-52862 (MR309): Esteve
ATX01: AlgoTherapeutix
WST-057 Active: WinSanTor, Inc
Olesoxime (TRO19622): Hoffmann-La Roche
Tetrodotoxin: Wex Pharma
Acupuncture: Millennium Pharma
leteprinim potassium (Neotrofin): NeoTherapeutics
Acetylcarnitine: Lee’s Pharma
Cesamet (nabilone): NEMA Research, Inc.

Discover more about therapies set to grab major Chemotherapy Induced Peripheral Neuropathy market share @ Chemotherapy Induced Peripheral Neuropathy Treatment Market

Chemotherapy Induced Peripheral Neuropathy Market Strengths

Certain initiatives have been taken by private and government organizations to raise awareness about the disease.
There has been an increase in pharmaceutical companies’ investment for the research and development of the drugs
Standardized assessment protocols and objective outcomes measures of CIPN applicable to patients of different ages are critical to enabling the development of novel treatments

Chemotherapy Induced Peripheral Neuropathy Market Opportunities

Several pharmaceutical key players have taken the initiative to meet the unmet needs of the CIPN market’s present situation.
The market also demands a proper diagnostic tools with well defined markers
Increased public awareness creates a lucrative opportunity for innovation of therapeutics to drive the CIPN market.

Scope of the Chemotherapy Induced Peripheral Neuropathy Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Chemotherapy Induced Peripheral Neuropathy Companies: Wex Pharmaceuticals, Esteve, AlgoTherapeutix, WinSanTor, Inc, Hoffmann-La Roche, Millennium Pharma, NeoTherapeutics, Lee’s Pharma, NEMA Research, Inc., and others
Key Chemotherapy Induced Peripheral Neuropathy Therapies: HALNEURON, E-52862 (MR309), ATX01, WST-057 Active, Olesoxime (TRO19622), Tetrodotoxi, Acupuncture, leteprinim potassium (Neotrofin), Acetylcarnitine, Cesamet (nabilone), and others
Chemotherapy Induced Peripheral Neuropathy Therapeutic Assessment: Chemotherapy Induced Peripheral Neuropathy current marketed and Chemotherapy Induced Peripheral Neuropathy emerging therapies
Chemotherapy Induced Peripheral Neuropathy Market Dynamics: Chemotherapy Induced Peripheral Neuropathy market drivers and Chemotherapy Induced Peripheral Neuropathy market barriers 
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chemotherapy Induced Peripheral Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy Induced Peripheral Neuropathy Market Access and Reimbursement 

To know more about Chemotherapy Induced Peripheral Neuropathy companies working in the treatment market, visit @ Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Chemotherapy Induced Peripheral Neuropathy Market Report Introduction

2. Executive Summary for Chemotherapy Induced Peripheral Neuropathy

3. SWOT analysis of Chemotherapy Induced Peripheral Neuropathy

4. Chemotherapy Induced Peripheral Neuropathy Patient Share (%) Overview at a Glance

5. Chemotherapy Induced Peripheral Neuropathy Market Overview at a Glance

6. Chemotherapy Induced Peripheral Neuropathy Disease Background and Overview

7. Chemotherapy Induced Peripheral Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Chemotherapy Induced Peripheral Neuropathy 

9. Chemotherapy Induced Peripheral Neuropathy Current Treatment and Medical Practices

10. Chemotherapy Induced Peripheral Neuropathy Unmet Needs

11. Chemotherapy Induced Peripheral Neuropathy Emerging Therapies

12. Chemotherapy Induced Peripheral Neuropathy Market Outlook

13. Country-Wise Chemotherapy Induced Peripheral Neuropathy Market Analysis (2019–2032)

14. Chemotherapy Induced Peripheral Neuropathy Market Access and Reimbursement of Therapies

15. Chemotherapy Induced Peripheral Neuropathy Market Drivers

16. Chemotherapy Induced Peripheral Neuropathy Market Barriers

17.  Chemotherapy Induced Peripheral Neuropathy Appendix

18. Chemotherapy Induced Peripheral Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services